Marieke van de Wal1,2, Simône Langenberg3, Marieke Gielissen4, Belinda Thewes1, Inge van Oort5, Judith Prins1. 1. Department of Medical Psychology, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Medical Psychology, Maxima Medical Center, Eindhoven/Veldhoven, The Netherlands. 3. Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Department of Psychology, Academic Medical Center, Amsterdam, The Netherlands. 5. Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
OBJECTIVES: The aims of the study were to (1) describe the prevalence of fear of cancer recurrence (FCR) in partners of prostate cancer (PCa) survivors; (2) to compare the proportions of high FCR in partners with high FCR in PCa survivors; (3) to explore partners' demographic and survivors' clinical characteristics associated with high FCR in partners; and (4) to identify the relationship between high FCR and health-related quality of life (HRQoL) in partners. METHODS: Questionnaires were sent to partners of disease-free PCa survivors. Outcomes included FCR severity (Cancer Worry Scale [CWS]) and HRQoL (RAND-36). The t and chi-square tests were used to compare partner FCR with survivor FCR. Regression analyses were performed to determine if demographic and clinical characteristics were significantly associated with partner FCR. The multivariate analysis of variance identified differences in HRQoL between partners with high and low FCR. RESULTS: Questionnaires were completed by 168 partners. Mean levels of FCR were comparable between partners and survivors (P = .144). Thirty-five percent of partners reported high FCR (CWS ≥ 14) compared to 38% of PCa survivors (CWS ≥ 13) (P = .542). Higher survivor FCR and younger partner age were significantly associated with higher partner FCR. Partners with high FCR scored significantly lower on social functioning, emotional role functioning, mental health, general health, and vitality than those with low FCR (all P < .05). CONCLUSIONS: Findings from this study illustrate that FCR is a significant concern for partners of PCa survivors. Clinicians should be aware of partner FCR when delivering care to men with PCa.
OBJECTIVES: The aims of the study were to (1) describe the prevalence of fear of cancer recurrence (FCR) in partners of prostate cancer (PCa) survivors; (2) to compare the proportions of high FCR in partners with high FCR in PCa survivors; (3) to explore partners' demographic and survivors' clinical characteristics associated with high FCR in partners; and (4) to identify the relationship between high FCR and health-related quality of life (HRQoL) in partners. METHODS: Questionnaires were sent to partners of disease-free PCa survivors. Outcomes included FCR severity (Cancer Worry Scale [CWS]) and HRQoL (RAND-36). The t and chi-square tests were used to compare partner FCR with survivor FCR. Regression analyses were performed to determine if demographic and clinical characteristics were significantly associated with partner FCR. The multivariate analysis of variance identified differences in HRQoL between partners with high and low FCR. RESULTS: Questionnaires were completed by 168 partners. Mean levels of FCR were comparable between partners and survivors (P = .144). Thirty-five percent of partners reported high FCR (CWS ≥ 14) compared to 38% of PCa survivors (CWS ≥ 13) (P = .542). Higher survivor FCR and younger partner age were significantly associated with higher partner FCR. Partners with high FCR scored significantly lower on social functioning, emotional role functioning, mental health, general health, and vitality than those with low FCR (all P < .05). CONCLUSIONS: Findings from this study illustrate that FCR is a significant concern for partners of PCa survivors. Clinicians should be aware of partner FCR when delivering care to men with PCa.
Authors: Spela Mirosevic; Belinda Thewes; Carla van Herpen; Johannes Kaanders; Thijs Merkx; Gerry Humphris; Robert J Baatenburg de Jong; Johannes A Langendijk; C René Leemans; Chris H J Terhaard; Irma M Verdonck-de Leeuw; Robert Takes; Judith Prins Journal: Head Neck Date: 2019-06-07 Impact factor: 3.147
Authors: Christina Sauer; Andreas Ihrig; Tobias Hanslmeier; Johannes Huber; Kiriaki Hiller; Hans-Christoph Friederich; Imad Maatouk Journal: Support Care Cancer Date: 2022-05-13 Impact factor: 3.359
Authors: Nina C A Vermeer; Maxime J M van der Valk; Heleen S Snijders; Hans F A Vasen; Arthur Gerritsen van der Hoop; Onno R Guicherit; Gerrit-Jan Liefers; Cornelis J H van de Velde; Anne M Stiggelbout; Koen C M J Peeters Journal: Psychooncology Date: 2020-04-14 Impact factor: 3.894
Authors: S M C H Langenberg; H Poort; A N M Wymenga; J W de Groot; E W Muller; W T A van der Graaf; J B Prins; C M L van Herpen Journal: Support Care Cancer Date: 2020-09-15 Impact factor: 3.603